Insulin glargine biosimilar - Boehringer Ingelheim/Eli Lilly

Drug Profile

Insulin glargine biosimilar - Boehringer Ingelheim/Eli Lilly

Alternative Names: Abasaglar; Abasria; Basalgar; LY-2963016; LY2963016 U-100; LY2963016 U-200

Latest Information Update: 11 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 21 Mar 2018 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in China (SC) (NCT03338010)
  • 17 Nov 2017 Eli Lilly plans a phase III trial for Type-1 diabetes mellitus (Combination therapy) in China in March 2018 (NCT03338023)
  • 17 Nov 2017 Eli Lilly plans a phase III trial for Type-2 diabetes mellitus (Adjunctive treatment) in China in February 2018 (NCT03338010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top